OM1’s Massive Real-World Dataset Could Set a New Standard for FDA Evidence Packages
OM1 says it supported FDA approval of Hologic’s Aptima HPV assay with a real-world submission based on data from 650,000 patients. The scale of the dataset underscores how real-world evidence is shifting from a nice-to-have supplement to a core regulatory asset.
OM1’s role in a 650,000-patient real-world regulatory submission is a strong indicator of where evidence generation is heading. Large-scale observational data are becoming more central to product approvals, especially when they can supplement or contextualize traditional clinical studies.
The size of the dataset is important, but the more significant point is what it represents: the industrialization of regulatory evidence. Vendors, diagnostics companies, and data platforms are learning that they can create value not just by developing tests or algorithms, but by packaging the evidence needed to persuade regulators and payers.
That shift could accelerate diagnostics innovation, particularly for products that already have strong use cases in routine care. It may also reduce time and cost barriers for bringing products to market, provided the underlying data are robust enough to support the claims being made.
At the same time, real-world evidence can easily be overhyped. A large dataset does not automatically produce a strong causal argument, and the FDA will still care about bias, confounding, missingness, and clinical relevance. The market is moving toward bigger evidence packages, but success will belong to companies that can turn scale into scientific credibility.